Tumor mutational burden is associated with poor outcomes in diffuse glioma

Tumor mutational burden is associated with poor outcomes in diffuse glioma

Abstract Background Tumor mutational burden (TMB) is a potential biomarker for immune checkpoint therapy and prognosis. The impact of TMB on clinical outcomes and the correlation coefficient between exome sequencing and targeted sequencing in glioma have not yet been explored. Methods Somatic mutati...

Full description

Bibliographic Details
Main Authors: Lihong Wang, Jia Ge, Yang Lan, Yu Shi, Ying Luo, Yuhuan Tan, Mei Liang, Song Deng, Xia Zhang, Wenying Wang, Yaoyao Tan, Yuanyuan Xu, Tao Luo
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
TMB
Glioma
Prognosis
Pan-cancer targeted sequencing
Online Access:http://link.springer.com/article/10.1186/s12885-020-6658-1

Internet

http://link.springer.com/article/10.1186/s12885-020-6658-1

Similar Items